Literature DB >> 7481479

Biochemical analysis of ferritin subunits in sera from adult Still's disease patients.

S Higashi1, T Ota, S Eto.   

Abstract

To determine the origin of the increased serum ferritin that occurs in adult Still's disease (ASD), we analyzed subunits of the serum ferritin as follows. Gel filtration with Sepharose CL-6B demonstrated that the molecular weight of serum ferritin was about 490 kDa. Western blot analysis revealed only L-subunits (molecular weight 19 kDa) in patients with serum ferritin levels higher than 1,000 ng/ml. Patients with serum ferritin levels higher than 1,000 ng/ml, however, showed G-subunits (molecular weight 23 kDa) in addition to the L-subunits. When concanavalin A (Con-A) Sepharose 4B was used in an absorption test, the percentage absorption was extremely low in the patients with serum ferritin levels higher than 1,000 ng/ml. Isoferritin patterns of the patients determined by chromatofocusing revealed traces of acidic ferritin. The findings suggested that glycosylated ferritin does not account for the major portion of the increased serum ferritin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7481479     DOI: 10.1007/bf00262707

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  24 in total

Review 1.  Ferritin in serum. Clinical and biochemical implications.

Authors:  A Jacobs; M Worwood
Journal:  N Engl J Med       Date:  1975-05-01       Impact factor: 91.245

2.  Immunological detection of isoferritins in normal human serum and tissue.

Authors:  L V McKeering; J W Halliday; J A Caffin; U Mack; L W Powell
Journal:  Clin Chim Acta       Date:  1976-03-01       Impact factor: 3.786

3.  Preliminary criteria for classification of adult Still's disease.

Authors:  M Yamaguchi; A Ohta; T Tsunematsu; R Kasukawa; Y Mizushima; H Kashiwagi; S Kashiwazaki; K Tanimoto; Y Matsumoto; T Ota
Journal:  J Rheumatol       Date:  1992-03       Impact factor: 4.666

4.  Suggested models of ecotaxopathy in lymphoreticular malignancy. A role for iron-binding proteins in the control of lymphoid cell migration.

Authors:  M de Sousa; A Smithyman; C Tan
Journal:  Am J Pathol       Date:  1978-02       Impact factor: 4.307

5.  Serum ferritin and its isoferritin patterns in homozygous beta-thalassemia.

Authors:  Y Yoshino; S Linpisarn; L Makonkawkeyoon; Y Hirai; S Hisayasu; H Orimo; M Kuga; T Sanguansermsri
Journal:  Nihon Ketsueki Gakkai Zasshi       Date:  1987-07

6.  Still's disease in the adult.

Authors:  E G Bywaters
Journal:  Ann Rheum Dis       Date:  1971-03       Impact factor: 19.103

7.  Tumor necrosis factor-alpha and interleukin 1-alpha regulate transferrin receptor in human diploid fibroblasts. Relationship to the induction of ferritin heavy chain.

Authors:  Y Tsuji; L L Miller; S C Miller; S V Torti; F M Torti
Journal:  J Biol Chem       Date:  1991-04-15       Impact factor: 5.157

8.  Serum ferritin in patients with iron overload and with acute and chronic liver diseases.

Authors:  J Prieto; M Barry; S Sherlock
Journal:  Gastroenterology       Date:  1975-03       Impact factor: 22.682

9.  Iron mobilization from ferritin by superoxide derived from stimulated polymorphonuclear leukocytes. Possible mechanism in inflammation diseases.

Authors:  P Biemond; H G van Eijk; A J Swaak; J F Koster
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

10.  Human serum ferritin G-peptide is recognized by anti-L ferritin subunit antibodies and concanavalin-A.

Authors:  P Santambrogio; A Cozzi; S Levi; P Arosio
Journal:  Br J Haematol       Date:  1987-02       Impact factor: 6.998

View more
  2 in total

1.  Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still's disease.

Authors:  S Vignes; G Le Moël; B Fautrel; B Wechsler; P Godeau; J C Piette
Journal:  Ann Rheum Dis       Date:  2000-05       Impact factor: 19.103

Review 2.  Hyperferritinemia and inflammation.

Authors:  Kate F Kernan; Joseph A Carcillo
Journal:  Int Immunol       Date:  2017-11-01       Impact factor: 4.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.